Pharmacological antioxidant strategies as therapeutic interventions for COPD

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 714-728

  Rahman, Irfan ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antioxidants; Chronic Obstructive Pulmonary Disease; Glutathione; Nrf2; Oxidants; Tobacco smoke

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; 3,4 DIHYDRO 4,4 DIMETHYL 1,3 BENZOSELENAZINE; ACETYLCYSTEINE; ACYSTELYN; AEOL 10113; AEOL 10150; ALT 2074; ANTIOXIDANT; BARDOXOLONE; BXT 51077; CARBOCISTEINE; CHALCONE DERIVATIVE; DISUFENTON SODIUM; EBSELEN; ERDOSTEINE; EUK 189; FUDOSTEINE; GLUTAREDOXIN; GLUTATHIONE ESTER; IMISOPASEM MANGANESE; ISOBUTYRYLCYSTEINE; LAZAROID; M 40419; M 4043; MANGANESE; MC 1856; NORPHENAZONE; PORPHYRIN DERIVATIVE; SALEN DERIVATIVE; SULFORAPHANE; THIONEINE; THIOREDOXIN; U 75412E; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DECOMPOSITION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG STRUCTURE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LIPID PEROXIDATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN CARBONYLATION; REVIEW; SPIN TRAPPING; TISSUE REPAIR;

ANTIOXIDANTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

NICOTIANA TABACUM;

EID: 84858155375     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.11.004     Document Type: Review

References (190)

1. Rahman I., Marwick J., Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem. Pharmacol. 2004, 68:1255-1267.
2. Yao H., Rahman I. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol. Appl. Pharmacol. 2011, 254:72-85.
3. Biswas S.K., Rahman I. Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. Mol. Aspects Med. 2009, 30:60-76.
4. Rahman I. Antioxidant therapeutic advances in COPD. Ther. Adv. Respir. Dis. 2008, 2:351-374.
5. Rahman I. Antioxidant therapies in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2006, 1:15-29.
6. Rahman I., Adcock I.M. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J. 2006, 28:219-242.
7. Makita H., Nasuhara Y., Nagai K., Ito Y., Hasegawa M., Betsuyaku T., Onodera Y., Hizawa N., Nishimura M. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007, 62:932-937.
8. Patel B., Make B., Coxson H.O., Muller N.L., Pillai S., Anderson W., Silverman E., Lomas D. Airway and parenchymal disease in chronic obstructive pulmonary disease are distinct phenotypes. Proc. Am. Thorac. Soc. 2006, 3:533.
9. Church D.F., Pryor W.A. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ. Health Perspect. 1985, 64:111-126.
10. Nakayama T., Church D.F., Pryor W.A. Quantitative analysis of the hydrogen peroxide formed in aqueous cigarette tar extracts. Free Radic. Biol. Med. 1989, 7:9-15.
11. Pryor W.A., Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann. N. Y. Acad. Sci. 1993, 686:12-27.
12. Aaron S.D., Angel J.B., Lunau M., Wright K., Fex C., Le Saux N., Dales R.E. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001, 163:349-355.
13. Gompertz S., Bayley D.L., Hill S.L., Stockley R.A. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001, 56:36-41.
14. Pinamonti S., Leis M., Barbieri A., Leoni D., Muzzoli M., Sostero S., Chicca M.C., Carrieri A., Ravenna F., Fabbri L.M., Ciaccia A. Detection of xanthine oxidase activity products by EPR and HPLC in bronchoalveolar lavage fluid from patients with chronic obstructive pulmonary disease. Free Radic. Biol. Med. 1998, 25:771-779.
15. Bindoli A., Fukuto J.M., Forman H.J. Thiol chemistry in peroxidase catalysis and redox signaling. Antioxid. Redox Signal. 2008, 10:1549-1564.
16. Montuschi P., Collins J.V., Ciabattoni G., Lazzeri N., Corradi M., Kharitonov S.A., Barnes P.J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 2000, 162:1175-1177.
17. Rahman I., van Schadewijk A.A., Crowther A.J., Hiemstra P.S., Stolk J., MacNee W., De Boer W.I. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002, 166:490-495.
18. Moretto N., Facchinetti F., Southworth T., Civelli M., Singh D., Patacchini R. alpha, beta-Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:L839-L848.
19. Rahman I., Morrison D., Donaldson K., MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am. J. Respir. Crit. Care Med. 1996, 154:1055-1060.
20. Rahman I., MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic. Biol. Med. 2000, 28:1405-1420.
21. Nicks M.E., O'Brien M.M., Bowler R.P. Plasma Antioxidants Are Associated with Impaired Lung Function and COPD Exacerbations in Smokers. COPD 2011, 8:264-269.
22. Garbin U., Fratta Pasini A., Stranieri C., Cominacini M., Pasini A., Manfro S., Lugoboni F., Mozzini C., Guidi G., Faccini G., Cominacini L. Cigarette smoking blocks the protective expression of Nrf2/ARE pathway in peripheral mononuclear cells of young heavy smokers favouring inflammation. PLoS One 2009, 4:e8225.
23. Rahman I., Biswas S.K., Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur. J. Pharmacol. 2006, 533:222-239.
24. Tuder R.M., Zhen L., Cho C.Y., Taraseviciene-Stewart L., Kasahara Y., Salvemini D., Voelkel N.F., Flores S.C. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am. J. Respir. Cell Mol. Biol. 2003, 29:88-97.
25. Muscoli C., Sacco I., Alecce W., Palma E., Nistico R., Costa N., Clementi F., Rotiroti D., Romeo F., Salvemini D., Mehta J.L., Mollace V. The protective effect of superoxide dismutase mimetic M40401 on balloon injury-related neointima formation: role of the lectin-like oxidized low-density lipoprotein receptor-1. J. Pharmacol. Exp. Ther. 2004, 311:44-50.
26. Chang L.Y., Crapo J.D. Inhibition of airway inflammation and hyperreactivity by an antioxidant mimetic. Free Radic. Biol. Med. 2002, 33:379-386.
27. Smith K.R., Uyeminami D.L., Kodavanti U.P., Crapo J.D., Chang L.Y., Pinkerton K.E. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic. Biol. Med. 2002, 33:1106-1114.
28. Sharpe M.A., Ollosson R., Stewart V.C., Clark J.B. Oxidation of nitric oxide by oxomanganese-salen complexes: a new mechanism for cellular protection by superoxide dismutase/catalase mimetics. Biochem. J. 2002, 366:97-107.
29. Nishikawa M., Kakemizu N., Ito T., Kudo M., Kaneko T., Suzuki M., Udaka N., Ikeda H., Okubo T. Superoxide mediates cigarette smoke-induced infiltration of neutrophils into the airways through nuclear factor-kappaB activation and IL-8 mRNA expression in guinea pigs in vivo. Am. J. Respir. Cell Mol. Biol. 1999, 20:189-198.
30. Day B.J., Shawen S., Liochev S.I., Crapo J.D. A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. J. Pharmacol. Exp. Ther. 1995, 275:1227-1232.
31. Day B.J., Fridovich I., Crapo J.D. Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide-mediated injury. Arch. Biochem. Biophys. 1997, 347:256-262.
32. Ferrer-Sueta G., Vitturi D., Batinic-Haberle I., Fridovich I., Goldstein S., Czapski G., Radi R. Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J. Biol. Chem. 2003, 278:27432-27438.
33. Tse H.M., Milton M.J., Piganelli J.D. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic. Biol. Med. 2004, 36:233-247.
34. Vujaskovic Z., Batinic-Haberle I., Rabbani Z.N., Feng Q.F., Kang S.K., Spasojevic I., Samulski T.V., Fridovich I., Dewhirst M.W., Anscher M.S. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic. Biol. Med. 2002, 33:857-863.
35. Piganelli J.D., Flores S.C., Cruz C., Koepp J., Batinic-Haberle I., Crapo J., Day B., Kachadourian R., Young R., Bradley B., Haskins K. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 2002, 51:347-355.
36. Zhang H.J., Doctrow S.R., Xu L., Oberley L.W., Beecher B., Morrison J., Oberley T.D., Kregel K.C. Redox modulation of the liver with chronic antioxidant enzyme mimetic treatment prevents age-related oxidative damage associated with environmental stress. FASEB J. 2004, 18:1547-1549.
37. Zhang H.J., Doctrow S.R., Oberley L.W., Kregel K.C. Chronic antioxidant enzyme mimetic treatment differentially modulates hyperthermia-induced liver HSP70 expression with aging. J. Appl. Physiol. 2006, 100:1385-1391.
38. Foronjy R.F., Mirochnitchenko O., Propokenko O., Lemaitre V., Jia Y., Inouye M., Okada Y., D'Armiento J.M. Superoxide dismutase expression attenuates cigarette smoke- or elastase-generated emphysema in mice. Am. J. Respir. Crit. Care Med. 2006, 173:623-631.
39. Clarke M.B., Wright R., Irwin D., Bose S., Van Rheen Z., Birari R., Stenmark K.R., McCord J.M., Nozik-Grayck E. Sustained lung activity of a novel chimeric protein, SOD2/3, after intratracheal administration. Free Radic. Biol. Med. 2010, 49:2032-2039.
40. Kinnula V.L., Crapo J.D. Superoxide dismutases in the lung and human lung diseases. Am. J. Respir. Crit. Care Med. 2003, 167:1600-1619.
41. Gongora M.C., Lob H.E., Landmesser U., Guzik T.J., Martin W.D., Ozumi K., Wall S.M., Wilson D.S., Murthy N., Gravanis M., Fukai T., Harrison D.G. Loss of extracellular superoxide dismutase leads to acute lung damage in the presence of ambient air: a potential mechanism underlying adult respiratory distress syndrome. Am. J. Pathol. 2008, 173:915-926.
42. Folz R.J., Abushamaa A.M., Suliman H.B. Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. J. Clin. Invest. 1999, 103:1055-1066.
43. Yao H., Arunachalam G., Hwang J.W., Chung S., Sundar I.K., Kinnula V.L., Crapo J.D., Rahman I. Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15571-15576.
44. Tollefson A.K., Oberley-Deegan R.E., Butterfield K.T., Nicks M.E., Weaver M.R., Remigio L.K., Decsesznak J., Chu H.W., Bratton D.L., Riches D.W., Bowler R.P. Endogenous enzymes (NOX and ECSOD) regulate smoke-induced oxidative stress. Free Radic. Biol. Med. 2010, 49:1937-1946.
45. Regan E.A., Mazur W., Meoni E., Toljamo T., Millar J., Vuopala K., Bowler R.P., Rahman I., Nicks M.E., Crapo J.D., Kinnula V.L. Smoking and COPD increase sputum levels of extracellular superoxide dismutase. Free Radic. Biol. Med. 2011, 51:726-732.
46. Sorheim I.C., DeMeo D.L., Washko G., Litonjua A., Sparrow D., Bowler R., Bakke P., Pillai S.G., Coxson H.O., Lomas D.A., Silverman E.K., Hersh C.P. Polymorphisms in the superoxide dismutase-3 gene are associated with emphysema in COPD. COPD 2010, 7:262-268.
47. Dahl M., Bowler R.P., Juul K., Crapo J.D., Levy S., Nordestgaard B.G. Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations. Am. J. Respir. Crit. Care Med. 2008, 178:906-912.
48. Jozsef L., Filep J.G. Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. Free Radic. Biol. Med. 2003, 35:1018-1027.
49. Haddad el B., McCluskie K., Birrell M.A., Dabrowski D., Pecoraro M., Underwood S., Chen B., De Sanctis G.T., Webber S.E., Foster M.L., Belvisi M.G. Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. J. Immunol. 2002, 169:974-982.
50. Zhang M., Nomura A., Uchida Y., Iijima H., Sakamoto T., Iishii Y., Morishima Y., Mochizuki M., Masuyama K., Hirano K., Sekizawa K. Ebselen suppresses late airway responses and airway inflammation in guinea pigs. Free Radic. Biol. Med. 2002, 32:454-464.
51. Moutet M., d'Alessio P., Malette P., Devaux V., Chaudiere J. Glutathione peroxidase mimics prevent TNFalpha- and neutrophil-induced endothelial alterations. Free Radic. Biol. Med. 1998, 25:270-281.
52. Stefanutti G., Pierro A., Smith V.V., Klein N.J., Eaton S. Peroxynitrite decomposition catalyst FeTMPyP provides partial protection against intestinal ischemia and reperfusion injury in infant rats. Pediatr. Res. 2007, 62:43-48.
53. Pacher P., Liaudet L., Bai P., Mabley J.G., Kaminski P.M., Virag L., Deb A., Szabo E., Ungvari Z., Wolin M.S., Groves J.T., Szabo C. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003, 107:896-904.
54. Cuzzocrea S., Thiemermann C., Salvemini D. Potential therapeutic effect of antioxidant therapy in shock and inflammation. Curr. Med. Chem. 2004, 11:1147-1162.
55. Chabrier P.E., Auguet M., Spinnewyn B., Auvin S., Cornet S., Demerle-Pallardy C., Guilmard-Favre C., Marin J.G., Pignol B., Gillard-Roubert V., Roussillot-Charnet C., Schulz J., Viossat I., Bigg D., Moncada S. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10824-10829.
56. Shi H., Timmins G., Monske M., Burdick A., Kalyanaraman B., Liu Y., Clement J.L., Burchiel S., Liu K.J. Evaluation of spin trapping agents and trapping conditions for detection of cell-generated reactive oxygen species. Arch. Biochem. Biophys. 2005, 437:59-68.
57. Becker D.A. Diagnostic and therapeutic applications of azulenyl nitrone spin traps. Cell. Mol. Life Sci. 1999, 56:626-633.
58. Bottle S.E., Micallef A.S. Synthesis and EPR spin trapping properties of a new isoindole-based nitrone: 1,1,3-trimethylisoindole N-oxide (TMINO). Org. Biomol. Chem. 2003, 1:2581-2584.
59. Becker D.A., Ley J.J., Echegoyen L., Alvarado R. Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants. J. Am. Chem. Soc. 2002, 124:4678-4684.
60. Valenca S.S., Rueff-Barroso C.R., Pimenta W.A., Melo A.C., Nesi R.T., Silva M.A., Porto L.C. L-NAME and L-arginine differentially ameliorate cigarette smoke-induced emphysema in mice. Pulm. Pharmacol. Ther. 2011, 24:587-594.
61. Seimetz M., Parajuli N., Pichl A., Veit F., Kwapiszewska G., Weisel F.C., Milger K., Egemnazarov B., Turowska A., Fuchs B., Nikam S., Roth M., Sydykov A., Medebach T., Klepetko W., Jaksch P., Dumitrascu R., Garn H., Voswinckel R., Kostin S., Seeger W., Schermuly R.T., Grimminger F., Ghofrani H.A., Weissmann N. Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. Cell 2011, 147:293-305.
62. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
63. Kumar V., Kumar S., Hassan M., Wu H., Thimmulappa R.K., Kumar A., Sharma S.K., Parmar V.S., Biswal S., Malhotra S.V. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. J. Med. Chem. 2011, 54:4147-4159.
64. Rangasamy T., Guo J., Mitzner W.A., Roman J., Singh A., Fryer A.D., Yamamoto M., Kensler T.W., Tuder R.M., Georas S.N., Biswal S. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. 2005, 202:47-59.
65. Sussan T.E., Rangasamy T., Blake D.J., Malhotra D., El-Haddad H., Bedja D., Yates M.S., Kombairaju P., Yamamoto M., Liby K.T., Sporn M.B., Gabrielson K.L., Champion H.C., Tuder R.M., Kensler T.W., Biswal S. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:250-255.
66. Wan J., Diaz-Sanchez D. Antioxidant enzyme induction: a new protective approach against the adverse effects of diesel exhaust particles. Inhal. Toxicol. 2007, 19:177-182.
67. Singh A., Rangasamy T., Thimmulappa R.K., Lee H., Osburn W.O., Brigelius-Flohe R., Kensler T.W., Yamamoto M., Biswal S. Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2. Am. J. Respir. Cell Mol. Biol. 2006, 35:639-650.
68. Rangasamy T., Cho C.Y., Thimmulappa R.K., Zhen L., Srisuma S.S., Kensler T.W., Yamamoto M., Petrache I., Tuder R.M., Biswal S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 2004, 114:1248-1259.
69. Iizuka T., Ishii Y., Itoh K., Kiwamoto T., Kimura T., Matsuno Y., Morishima Y., Hegab A.E., Homma S., Nomura A., Sakamoto T., Shimura M., Yoshida A., Yamamoto M., Sekizawa K. Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 2005, 10:1113-1125.
70. Goven D., Boutten A., Lecon-Malas V., Marchal-Somme J., Amara N., Crestani B., Fournier M., Leseche G., Soler P., Boczkowski J., Bonay M. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax 2008, 63:916-924.
71. Malhotra D., Thimmulappa R., Navas-Acien A., Sandford A., Elliott M., Singh A., Chen L., Zhuang X., Hogg J., Pare P., Tuder R.M., Biswal S. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am. J. Respir. Crit. Care Med. 2008, 178:592-604.
72. Suzuki M., Betsuyaku T., Ito Y., Nagai K., Nasuhara Y., Kaga K., Kondo S., Nishimura M. Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2008, 39:673-682.
73. Mercado N., Thimmulappa R., Thomas C.M., Fenwick P.S., Chana K.K., Donnelly L.E., Biswal S., Ito K., Barnes P.J. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun. 2011, 406:292-298.
74. Adenuga D., Caito S., Yao H., Sundar I.K., Hwang J.W., Chung S., Rahman I. Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction. Biochem. Biophys. Res. Commun. 2010, 403:452-456.
75. Yang S.R., Chida A.S., Bauter M.R., Shafiq N., Seweryniak K., Maggirwar S.B., Kilty I., Rahman I. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 291:L46-L57.
76. Meja K.K., Rajendrasozhan S., Adenuga D., Biswas S.K., Sundar I.K., Spooner G., Marwick J.A., Chakravarty P., Fletcher D., Whittaker P., Megson I.L., Kirkham P.A., Rahman I. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am. J. Respir. Cell Mol. Biol. 2008, 39:312-323.
77. Adenuga D., Yao H., March T.H., Seagrave J., Rahman I. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am. J. Respir. Cell Mol. Biol. 2009, 40:464-473.
78. Osoata G.O., Yamamura S., Ito M., Vuppusetty C., Adcock I.M., Barnes P.J., Ito K. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem. Biophys. Res. Commun. 2009, 384:366-371.
79. Nott A., Watson P.M., Robinson J.D., Crepaldi L., Riccio A. S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 2008, 455:411-415.
80. Malhotra D., Thimmulappa R.K., Mercado N., Ito K., Kombairaju P., Kumar S., Ma J., Feller-Kopman D., Wise R., Barnes P., Biswal S. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J. Clin. Invest. 2011, 121:4289-4302.
81. Doyle K., Fitzpatrick F.A. Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J. Biol. Chem. 2010, 285:17417-17424.
82. Thimmulappa R.K., Mai K.H., Srisuma S., Kensler T.W., Yamamoto M., Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 2002, 62:5196-5203.
83. Kwak M.K., Wakabayashi N., Itoh K., Motohashi H., Yamamoto M., Kensler T.W. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 2003, 278:8135-8145.
84. Balogun E., Hoque M., Gong P., Killeen E., Green C.J., Foresti R., Alam J., Motterlini R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 2003, 371:887-895.
85. Go M.L., Wu X., Liu X.L. Chalcones: an update on cytotoxic and chemoprotective properties. Curr. Med. Chem. 2005, 12:481-499.
86. Wei B.L., Teng C.H., Wang J.P., Won S.J., Lin C.N. Synthetic 2',5'-dimethoxychalcones as G(2)/M arrest-mediated apoptosis-inducing agents and inhibitors of nitric oxide production in rat macrophages. Eur. J. Med. Chem. 2007, 42:660-668.
87. Lee J.H., Jung H.S., Giang P.M., Jin X., Lee S., Son P.T., Lee D., Hong Y.S., Lee K., Lee J.J. Blockade of nuclear factor-kappaB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J. Pharmacol. Exp. Ther. 2006, 316:271-278.
88. Liu Y.C., Hsieh C.W., Wu C.C., Wung B.S. Chalcone inhibits the activation of NF-kappaB and STAT3 in endothelial cells via endogenous electrophile. Life Sci. 2007, 80:1420-1430.
89. Foresti R., Hoque M., Monti D., Green C.J., Motterlini R. Differential activation of heme oxygenase-1 by chalcones and rosolic acid in endothelial cells. J. Pharmacol. Exp. Ther. 2005, 312:686-693.
90. Li Y., Liu W., Xing G., Tian C., Zhu Y., He F. Direct association of hepatopoietin with thioredoxin constitutes a redox signal transduction in activation of AP-1/NF-kappaB. Cell. Signal. 2005, 17:985-996.
91. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998, 17:2596-2606.
92. Qin J., Clore G.M., Kennedy W.M., Huth J.R., Gronenborn A.M. Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF kappa B. Structure 1995, 3:289-297.
93. Souza D.G., Vieira A.T., Pinho V., Sousa L.P., Andrade A.A., Bonjardim C.A., McMillan M., Kahn M., Teixeira M.M. NF-kappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury. Br. J. Pharmacol. 2005, 145:246-254.
94. Nguyen C., Teo J.L., Matsuda A., Eguchi M., Chi E.Y., Henderson W.R., Kahn M. Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1169-1173.
95. Henderson W.R., Chi E.Y., Teo J.L., Nguyen C., Kahn M. A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J. Immunol. 2002, 169:5294-5299.
96. Sato A., Hoshino Y., Hara T., Muro S., Nakamura H., Mishima M., Yodoi J. Thioredoxin-1 ameliorates cigarette smoke-induced lung inflammation and emphysema in mice. J. Pharmacol. Exp. Ther. 2008, 325:380-388.
97. Bachnoff N., Trus M., Atlas D. Alleviation of oxidative stress by potent and selective thioredoxin-mimetic peptides. Free Radic. Biol. Med. 2011, 50:1355-1367.
98. Hofmann B., Hecht H.J., Flohe L. Peroxiredoxins. Biol. Chem. 2002, 383:347-364.
99. Wood Z.A., Schroder E., Robin Harris J., Poole L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 2003, 28:32-40.
100. Mo Y., Feinstein S.I., Manevich Y., Zhang Q., Lu L., Ho Y.S., Fisher A.B. 1-Cys peroxiredoxin knock-out mice express mRNA but not protein for a highly related intronless gene. FEBS Lett. 2003, 555:192-198.
101. Kim T.S., Dodia C., Chen X., Hennigan B.B., Jain M., Feinstein S.I., Fisher A.B. Cloning and expression of rat lung acidic Ca(2+)-independent PLA2 and its organ distribution. Am. J. Physiol. 1998, 274:L750-L761.
102. Lee S.B., Ho J.N., Yoon S.H., Kang G.Y., Hwang S.G., Um H.D. Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt. Mol. Cells 2009, 28:583-588.
103. Neumann C.A., Krause D.S., Carman C.V., Das S., Dubey D.P., Abraham J.L., Bronson R.T., Fujiwara Y., Orkin S.H., Van Etten R.A. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003, 424:561-565.
104. Sundar I.K., Chung S., Hwang J.W., Arunachalam G., Cook S., Yao H., Mazur W., Kinnula V.L., Fisher A.B., Rahman I. Peroxiredoxin 6 differentially regulates acute and chronic cigarette smoke-mediated lung inflammatory response and injury. Exp. Lung Res. 2010, 36:451-462.
105. Chung S., Sundar I.K., Yao H., Ho Y.S., Rahman I. Glutaredoxin 1 regulates cigarette smoke-mediated lung inflammation through differential modulation of I{kappa}B kinases in mice: impact on histone acetylation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299:L192-L203.
106. Reynaert N.L., van der Vliet A., Guala A.S., McGovern T., Hristova M., Pantano C., Heintz N.H., Heim J., Ho Y.S., Matthews D.E., Wouters E.F., Janssen-Heininger Y.M. Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13086-13091.
107. Peltoniemi M.J., Rytila P.H., Harju T.H., Soini Y.M., Salmenkivi K.M., Ruddock L.W., Kinnula V.L. Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease. Respir. Res. 2006, 7:133.
108. Kuipers I., Guala A.S., Aesif S.W., Konings G., Bouwman F.G., Mariman E.C., Wouters E.F., Janssen-Heininger Y.M., Reynaert N.L. Cigarette Smoke Targets Glutaredoxin 1, Increasing S-glutathionylation and Epithelial Cell Death. Am. J. Respir. Cell Mol. Biol. 2011, 45:931-937.
109. Rubio M.L., Martin-Mosquero M.C., Ortega M., Peces-Barba G., Gonzalez-Mangado N. Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest 2004, 125:1500-1506.
110. Decramer M., Dekhuijzen P.N., Troosters T., van Herwaarden C., Rutten-van Molken M., van Schayck C.P., Olivieri D., Lankhorst I., Ardia A. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee. Eur. Respir. J. 2001, 17:329-336.
111. Decramer M., Rutten-van Molken M., Dekhuijzen P.N., Troosters T., van Herwaarden C., Pellegrino R., van Schayck C.P., Olivieri D., Del Donno M., De Backer W., Lankhorst I., Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005, 365:1552-1560.
112. Poole P.J., Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001, 322:1271-1274.
113. Poole P.J., Black P.N. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am. J. Respir. Med. 2003, 2:367-370.
114. Stey C., Steurer J., Bachmann S., Medici T.C., Tramer M.R. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000, 16:253-262.
115. Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 2000, 22:209-221.
116. Bridgeman M.M., Marsden M., Selby C., Morrison D., MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994, 49:670-675.
117. Kasielski M., Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir. Med. 2001, 95:448-456.
118. Black P.N., Morgan-Day A., McMillan T.E., Poole P.J., Young R.P. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC Pulm. Med. 2004, 4:13.
119. van Overveld F.J., Demkow U., Gorecka D., de Backer W.A., Zielinski J. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J. Physiol. Pharmacol. 2005, 56:135-142.
120. De Benedetto F., Aceto A., Dragani B., Spacone A., Formisano S., Pela R., Donner C.F., Sanguinetti C.M. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm. Pharmacol. Ther. 2005, 18:41-47.
121. Moretti M., Bottrighi P., Dallari R., Da Porto R., Dolcetti A., Grandi P., Garuti G., Guffanti E., Roversi P., De Gugliemo M., Potena A. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp. Clin. Res. 2004, 30:143-152.
122. Zheng J.P., Kang J., Huang S.G., Chen P., Yao W.Z., Yang L., Bai C.X., Wang C.Z., Wang C., Chen B.Y., Shi Y., Liu C.T., Li Q., Wang Z.S., Huang Y.J., Luo Z.Y., Chen F.P., Yuan J.Z., Yuan B.T., Qian H.P., Zhi R.C., Zhong N.S. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008, 371:2013-2018.
123. Dekhuijzen P.N. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur. Respir. J. 2004, 23:629-636.
124. Van Schooten F.J., Besaratinia A., De Flora S., D'Agostini F., Izzotti A., Camoirano A., Balm A.J., Dallinga J.W., Bast A., Haenen G.R., Van't Veer L., Baas P., Sakai H., Van Zandwijk N. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol. Biomarkers Prev. 2002, 11:167-175.
125. Koechlin C., Couillard A., Cristol J.P., Chanez P., Hayot M., Le Gallais D., Prefaut C. Does systemic inflammation trigger local exercise-induced oxidative stress in COPD?. Eur. Respir. J. 2004, 23:538-544.
126. Dueholm M., Nielsen C., Thorshauge H., Evald T., Hansen N.C., Madsen H.D., Maltbaek N. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir. Med. 1992, 86:89-92.
127. Gerrits C.M., Herings R.M., Leufkens H.G., Lammers J.W. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2003, 21:795-798.
128. Mata M., Morcillo E., Gimeno C., Cortijo J. N-acetyl-l-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem. Pharmacol. 2011, 82:548-555.
129. Gillissen A., Jaworska M., Orth M., Coffiner M., Maes P., App E.M., Cantin A.M., Schultze-Werninghaus G. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir. Med. 1997, 91:159-168.
130. Hardy J.G., Newman S.P., Knoch M. Lung deposition from four nebulizers. Respir. Med. 1993, 87:461-465.
131. Guidot D.M., Brown L.A. Mitochondrial glutathione replacement restores surfactant synthesis and secretion in alveolar epithelial cells of ethanol-fed rats. Alcohol. Clin. Exp. Res. 2000, 24:1070-1076.
132. Hodge S., Matthews G., Mukaro V., Ahern J., Shivam A., Hodge G., Holmes M., Jersmann H., Reynolds P.N. Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. Am. J. Respir. Cell Mol. Biol. 2011, 44:673-681.
133. Butterworth M., Upshall D.G., Hobbs M., Cohen G.M. Elevation of cysteine and replenishment of glutathione in rat lung slices by cysteine isopropylester and other cysteine precursors. Biochem. Pharmacol. 1993, 45:1769-1774.
134. Ekberg-Jansson A., Larson M., MacNee W., Tunek A., Wahlgren L., Wouters E.F., Larsson S. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur. Respir. J. 1999, 13:829-834.
135. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2007, 1:307-316.
136. Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin. Drug Metab. Toxicol. 2009, 5:333-343.
137. Cazzola M., Floriani I., Page C.P. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm. Pharmacol. Ther. 2010, 23:135-144.
138. Dal Negro R.W. Erdosteine: antitussive and anti-inflammatory effects. Lung 2008, 186(Suppl. 1):S70-S73.
139. Dal Negro R.W., Visconti M., Tognella S., Micheletto C. Erdosteine affects eicosanoid production in COPD. Int. J. Clin. Pharmacol. Ther. 2011, 49:41-45.
140. Braga P.C., Allegra L., Rampoldi C., Ornaghi A., Beghi G. Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration 1990, 57:353-358.
141. Carpagnano G.E., Resta O., Foschino-Barbaro M.P., Spanevello A., Stefano A., Di Gioia G., Serviddio G., Gramiccioni E. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate. Eur. J. Pharmacol. 2004, 505:169-175.
142. Hanaoka M., Droma Y., Chen Y., Agatsuma T., Kitaguchi Y., Voelkel N.F., Kubo K. Carbocisteine protects against emphysema induced by cigarette smoke extract in rats. Chest 2011, 139:1101-1108.
143. Asti C., Melillo G., Caselli G.F., Daffonchio L., Hernandez A., Clavenna G., Omini C. Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness. Pharmacol. Res. 1995, 31:387-392.
144. Ishibashi Y., Okamura T., Masumoto Y., Tachiiri T., Momo K. Effects of carbocisteine on airway inflammation and related events in SO2-exposed rats. Nihon Kokyuki Gakkai Zasshi 2001, 39:17-23.
145. Zheng C.H., Ahmed K., Rikitomi N., Martinez G., Nagatake T. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol. Immunol. 1999, 43:107-113.
146. Cakan G., Turkoz M., Turan T., Ahmed K., Nagatake T. S-carboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells. Microb. Pathog. 2003, 34:261-265.
147. Tatsumi K., Fukuchi Y. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 2007, 55:1884-1886.
148. Aylward M. An assessment of S-carboxymethylcysteine in the treatment of chronic bronchitis. Curr. Med. Res. Opin. 1974, 2:387-394.
149. Edwards G.F., Steel A.E., Scott J.K., Jordan J.W. S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction. Chest 1976, 70:506-513.
150. Miskoviti G., Szule P., Mescaros K. Double blind study of carbocysteine against placebo in chronic bronchitis; Mucoregulation in respiratory tract disorders. Proc. R. Soc. Med. 1982, 5:1-3.
151. Puchelle E., Girard F., Zahm J.M. Rheology of bronchial secretions and mucociliary transport (author's transl). Bull. Eur. Physiopathol. Respir. 1976, 12:771-779.
152. Allegra L., Cordaro C.I., Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration 1996, 63:174-180.
153. Grillage M., Barnard-Jones K. Long-term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. Br. J. Clin. Pract. 1985, 39:395-398.
154. Yasuda H., Yamaya M., Sasaki T., Inoue D., Nakayama K., Tomita N., Yoshida M., Sasaki H. Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 2006, 54:378-380.
155. Yasuda H., Yamaya M., Sasaki T., Inoue D., Nakayama K., Yamada M., Asada M., Yoshida M., Suzuki T., Nishimura H., Sasaki H. Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur. Respir. J. 2006, 28:51-58.
156. Rhee C.K., Kang C.M., You M.B., Yoon H.K., Kim Y.K., Kim K.H., Moon H.S., Park S.H., Song J.S. Effect of fudosteine on mucin production. Eur. Respir. J. 2008, 32:1195-1202.
157. Komatsu H., Yamaguchi S., Komorita N., Goto K., Takagi S., Ochi H., Okumoto T. Inhibition of endotoxin- and antigen-induced airway inflammation by fudosteine, a mucoactive agent. Pulm. Pharmacol. Ther. 2005, 18:121-127.
158. Nagaoka S., Takishima T., Nagano H., Kawakami Y., Kitamua S., Kawakami M., Ogura T., Sasaki T., Ogawa N. Phase III Clinical Study of SS320A. Double-blind Trial in Comparison with Placebo. J. Clin. Ther. Med. 2002, 18:109-140.
159. Takahashi K., Iwase N., Ishikawa M., Mizuno H., Koda T., Kai H., Miyata T. Effects of fudosteine, a new cysteine derivative, on airway secretion in rabbits and rats. Nihon Yakurigaku Zasshi 2000, 116:371-378.
160. Osoata G.O., Hanazawa T., Brindicci C., Ito M., Barnes P.J., Kharitonov S., Ito K. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest 2009, 135:1513-1520.
161. Moncaster J.A., Walsh D.T., Gentleman S.M., Jen L.S., Aruoma O.I. Ergothioneine treatment protects neurons against N-methyl-D-aspartate excitotoxicity in an in vivo rat retinal model. Neurosci. Lett. 2002, 328:55-59.
162. Aruoma O.I., Whiteman M., England T.G., Halliwell B. Antioxidant action of ergothioneine: assessment of its ability to scavenge peroxynitrite. Biochem. Biophys. Res. Commun. 1997, 231:389-391.
163. Aruoma O.I., Spencer J.P., Mahmood N. Protection against oxidative damage and cell death by the natural antioxidant ergothioneine. Food Chem. Toxicol. 1999, 37:1043-1053.
164. Misiti F., Castagnola M., Zuppi C., Giardina B., Messana I. Role of ergothioneine on S-nitrosoglutathione catabolism. Biochem. J. 2001, 356:799-804.
165. Rahman I., Gilmour P.S., Jimenez L.A., Biswas S.K., Antonicelli F., Aruoma O.I. Ergothioneine inhibits oxidative stress- and TNF-alpha-induced NF-kappa B activation and interleukin-8 release in alveolar epithelial cells. Biochem. Biophys. Res. Commun. 2003, 302:860-864.
166. Tajima S., Bando M., Ishii Y., Hosono T., Yamasawa H., Ohno S., Takada T., Suzuki E., Gejyo F., Sugiyama Y. Effects of edaravone, a free-radical scavenger, on bleomycin-induced lung injury in mice. Eur. Respir. J. 2008, 32:1337-1343.
167. Kikuchi K., Uchikado H., Miyagi N., Morimoto Y., Ito T., Tancharoen S., Miura N., Miyata K., Sakamoto R., Kikuchi C., Iida N., Shiomi N., Kuramoto T., Kawahara K. Beyond neurological disease: New targets for edaravone (Review). Int. J. Mol. Med. 2011, 28:899-906.
168. Aldini G., Vistoli G., Regazzoni L., Benfatto M.C., Bettinelli I., Carini M. Edaravone inhibits protein carbonylation by a direct carbonyl-scavenging mechanism: focus on reactivity, selectivity, and reaction mechanisms. Antioxid. Redox Signal. 2010, 12:381-392.
169. Kirkham P.A., Caramori G., Casolari P., Papi A.A., Edwards M., Shamji B., Triantaphyllopoulos K., Hussain F., Pinart M., Khan Y., Heinemann L., Stevens L., Yeadon M., Barnes P.J., Chung K.F., Adcock I.M. Oxidative Stress-induced Antibodies to Carbonyl-modified Protein Correlate with Severity of Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2011, 184:796-802.
170. Aldini G., Dalle-Donne I., Facino R.M., Milzani A., Carini M. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med. Res. Rev. 2007, 27:817-868.
171. Kawai H., Nakai H., Suga M., Yuki S., Watanabe T., Saito K.I. Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. 1997, 281:921-927.
172. Watanabe T., Yuki S., Egawa M., Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 1994, 268:1597-1604.
173. Wu T.W., Zeng L.H., Wu J., Fung K.P. MCI-186: further histochemical and biochemical evidence of neuroprotection. Life Sci. 2000, 67:2387-2392.
174. Ito K., Ozasa H., Horikawa S. Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. Free Radic. Biol. Med. 2005, 38:369-374.
175. Yang T., Mao Y.F., Liu S.Q., Hou J., Cai Z.Y., Hu J.Y., Ni X., Deng X.M., Zhu X.Y. Protective effects of the free radical scavenger edaravone on acute pancreatitis-associated lung injury. Eur. J. Pharmacol. 2010, 630:152-157.
176. Asai T., Ohno Y., Minatoguchi S., Funaguchi N., Yuhgetsu H., Sawada M., Takemura G., Komada A., Fujiwara T., Fujiwara H. The specific free radical scavenger edaravone suppresses bleomycin-induced acute pulmonary injury in rabbits. Clin. Exp. Pharmacol. Physiol. 2007, 34:22-26.
177. Zhi Q., Sun H., Qian X., Yang L. Edaravone, a novel antidote against lung injury and pulmonary fibrosis induced by paraquat?. Int. Immunopharmacol. 2011, 11:96-102.
178. Yoshizaki A., Yanaba K., Ogawa A., Iwata Y., Ogawa F., Takenaka M., Shimizu K., Asano Y., Kadono T., Sato S. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum. 2011, 63:3086-3097.
179. Fujita M., Mizuta Y., Ikegame S., Ouchi H., Ye Q., Harada E., Inoshima I., Yoshimi M., Watanabe K., Nakanishi Y. Biphasic effects of free radical scavengers against bleomycin-induced pulmonary fibrosis. Pulm. Pharmacol. Ther. 2008, 21:805-811.
180. Braughler J.M., Pregenzer J.F., Chase R.L., Duncan L.A., Jacobsen E.J., McCall J.M. Novel 21-amino steroids as potent inhibitors of iron-dependent lipid peroxidation. J. Biol. Chem. 1987, 262:10438-10440.
181. Miniati M., Cocci F., Monti S., Filippi E., Sarnelli R., Ferdeghini M., Gattai V., Pistolesi M. Lazaroid U-74389F attenuates phorbol ester-induced lung injury in rabbits. Eur. Respir. J. 1996, 9:758-764.
182. Shenkar R., Abraham E. Effects of treatment with the 21-aminosteroid, U7438F, on pulmonary cytokine expression following hemorrhage and resuscitation. Crit. Care Med. 1995, 23:132-139.
183. Wang S., Lantz R.C., Rider E.D., Chen G.J., Breceda V., Hays A.M., Robledo R.F., Tollinger B.J., Dinesh S.V., Witten M.L. A free radical scavenger (Lazaroid U75412E) attenuates tumor necrosis factor-alpha generation in a rabbit model of smoke-induced lung injury. Respiration 1997, 64:358-363.
184. Wang S., Lantz R.C., Vermeulen M.W., Chen G.J., Breceda V., Robledo R.F., Hays A.M., Young S., Witten M.L. Functional alterations of alveolar macrophages subjected to smoke exposure and antioxidant lazaroids. Toxicol. Ind. Health 1999, 15:464-469.
185. Tanigaki T., Suzuki Y., Heimer D., Sussman H.H., Ross W.G., Raffin T.A. Attenuation of acute lung injury and oxygen radical production by the 21-aminosteroid, U-78518F. J. Appl. Physiol. 1993, 74:2155-2160.
186. van Klaveren R.J., Roelant C., Boogaerts M., Pype J.L., Demedts M., Nemery B. Protective effects of the lazaroid U-74389G against hyperoxia in rat type II pneumocytes. Pulm. Pharmacol. Ther. 1998, 11:23-30.
187. Kubo K., Amari T., Kaneki T., Hanaoka M., Hayano T., Miyahara T., Koyama S., Koizumi T., Fujimoto K., Kobayashi T. A 21-aminosteroid, U-74006F, attenuates endotoxin-induced lung injury in awake sheep. Respirology 1999, 4:167-172.
188. Fujimoto K., Kubo K., Okada K., Kobayashi T., Sekiguchi M., Sakai A. Effect of the 21-aminosteroid U-74006F on antigen-induced bronchoconstriction and bronchoalveolar eosinophilia in allergic sheep. Eur. Respir. J. 1996, 9:2044-2049.
189. Nakayama M., Hasegawa N., Oka Y., Lutzke B., McCall J.M., Raffin T.A. Effects of the lazaroid, tirilazad mesylate, on sepsis-induced acute lung injury in minipigs. Crit. Care Med. 1998, 26:538-547.
190. Griffin R.L., Krzesicki R.F., Fidler S.F., Rosenbloom C.L., Auchampach J.A., Manning A.M., Haas J.V., Cammarata S.K., Chin J.E., Richards I.M. Attenuation of oxidant-induced lung injury by 21-aminosteroids (lazaroids): correlation with the mRNA expression for E-selectin, P-selectin, ICAM-1, and VCAM-1. Environ. Health Perspect. 1994, 102(Suppl. 10):193-200.